NCT07543848: A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer

Sponsor: Chongqing University Cancer Hospital. Phase: PHASE2. Conditions: Rectal Neoplasms, Rectal Adenocarcinoma